

# Luca Pani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2047060/publications.pdf>

Version: 2024-02-01

181  
papers

6,180  
citations

71102

41  
h-index

82547

72  
g-index

187  
all docs

187  
docs citations

187  
times ranked

8784  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Oral Cannabinoid Preparations for the Treatment of Chronic Migraine: A Retrospective Study. <i>Pain Medicine</i> , 2022, 23, 396-402.  | 1.9 | 5         |
| 2  | Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. <i>Neurological Sciences</i> , 2022, 43, 3823-3830.   | 1.9 | 11        |
| 3  | Occlusal splint therapy in patients with MÃ©niÃ©re's disease and temporomandibular joint disorder. <i>Acta Otorhinolaryngologica Italica</i> , 2022, , 1-8.  | 1.5 | 1         |
| 4  | A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. <i>Molecular Psychiatry</i> , 2022, 27, 1286-1299.   | 7.9 | 68        |
| 5  | Case Report: REL-1017 Reduces Abnormal Clinician Administered Dissociative States Scale Scores in Patients with Major Depressive Disorder. <i>CNS Spectrums</i> , 2022, 27, 236-236.                                   | 1.2 | 0         |
| 6  | A Phase 2a Double-Blind Randomized Trial of REL-1017 (Esmethadone) in Patients with MDD: Analysis of Subscales from the Symptoms of Depression Questionnaire. <i>CNS Spectrums</i> , 2022, 27, 235-235.                | 1.2 | 3         |
| 7  | Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. <i>Neurological Sciences</i> , 2021, 42, 4193-4202. | 1.9 | 20        |
| 8  | Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic. <i>Frontiers in Neurology</i> , 2021, 12, 647995.   | 2.4 | 5         |
| 9  | New Models for the Evaluation of Specialized Medicinal Products: Beyond Conventional Health Technology Assessment and Pricing. <i>Clinical Drug Investigation</i> , 2021, 41, 529-537.                                 | 2.2 | 1         |
| 10 | Digital Phenotyping and Dynamic Monitoring of Adolescents Treated for Cancer to Guide Intervention: Embracing a New Era. <i>Frontiers in Oncology</i> , 2021, 11, 673581.  | 2.8 | 13        |
| 11 | Predictors of response to erenumab after 12 months of treatment. <i>Brain and Behavior</i> , 2021, 11, e2260.  | 2.2 | 34        |
| 12 | Biomarkers and Surrogate End points in Multiple Sclerosis Trials: Regulatory Issues. <i>Journal of Clinical Neurophysiology</i> , 2021, 38, 181-185.   | 1.7 | 1         |
| 13 | A case-control study of visually evoked postural responses in childhood with primary headaches. <i>Neurological Sciences</i> , 2020, 41, 305-311.  | 1.9 | 4         |
| 14 | The endless frontier? The recent increase of R&D productivity in pharmaceuticals. <i>Journal of Translational Medicine</i> , 2020, 18, 162.  | 4.4 | 42        |
| 15 | Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. <i>Journal of Psychopharmacology</i> , 2019, 33, 1039-1057.  | 4.0 | 121       |
| 16 | Approaches to attenuated psychosis syndrome treatments: A perspective on the regulatory issues. <i>Schizophrenia Research: Cognition</i> , 2019, 18, 100155.   | 1.3 | 3         |
| 17 | Nutraceuticals: opening the debate for a regulatory framework. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 659-672.  | 2.4 | 246       |
| 18 | The Italian compassionate use of sofosbuvir in <sc>HCV</sc> patients waitlisted for liver transplantation: A national real-life experience. <i>Liver International</i> , 2018, 38, 733-741.                            | 3.9 | 5         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 738-763.   | 2.4  | 3         |
| 20 | Take This Cognitive Training Efficacy Bar Fight Outside (to a Regulatory Agency). <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 900-902.  | 1.5  | 0         |
| 21 | Safety of Antiplatelet Agents: Analysis of "Real-World" Data from the Italian National Pharmacovigilance Network. <i>Clinical Drug Investigation</i> , 2017, 37, 1067-1081.  | 2.2  | 7         |
| 22 | Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434. | 8.1  | 15        |
| 23 | The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. <i>Transplant International</i> , 2017, 30, 1253-1265.   | 1.6  | 3         |
| 24 | Scaling up health knowledge at European level requires sharing integrated data: an approach for collection of database specification. <i>ClinicoEconomics and Outcomes Research</i> , 2016, 8, 253.  | 1.9  | 6         |
| 25 | Kounis syndrome due to antibiotics: A global overview from pharmacovigilance databases. <i>International Journal of Cardiology</i> , 2016, 224, 406-411.   | 1.7  | 14        |
| 26 | Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR). <i>Pharmacological Research</i> , 2016, 111, 247-250.   | 7.1  | 9         |
| 27 | Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 730-742.   | 4.7  | 20        |
| 28 | Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 168-172.   | 2.5  | 32        |
| 29 | Identification and validation of biomarkers for autism spectrum disorders. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 70-70.   | 46.4 | 117       |
| 30 | Kounis Syndrome: An analysis of spontaneous reports from international pharmacovigilance database. <i>International Journal of Cardiology</i> , 2016, 203, 217-220.  | 1.7  | 36        |
| 31 | Adherence to Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Prescriptions Affects Overall Medication Adherence in Older Persons. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1712-1718.   | 2.2  | 10        |
| 32 | Association of neovascular age-related macular degeneration with month and season of birth in Italy. <i>Aging</i> , 2016, 9, 133-141.  | 3.1  | 3         |
| 33 | MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 210-213.  | 0.5  | 44        |
| 34 | Transparency in medical research: Time for a paradigm shift. <i>Clinical Trials and Regulatory Science in Cardiology</i> , 2015, 2-3, 1-3.   | 1.0  | 0         |
| 35 | Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model. <i>Pharmacological Research</i> , 2015, 102, 12-21.   | 7.1  | 9         |
| 36 | Generic and biosimilar medicines use and expenditure: A report from the National Observatory on the Use of Medicines (OsMed) of the Italian Medicines Agency (AIFA). <i>Journal of Generic Medicines</i> , 2015, 12, 79-80.  | 0.2  | 1         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | The future is now: Model-based clinical trial design for Alzheimer's disease. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 210-214.   | 4.7  | 68        |
| 38 | Alternative Pricing Strategies for Cancer Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 857.   | 7.4  | 10        |
| 39 | An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin. <i>BioDrugs</i> , 2015, 29, 285-300.  | 4.6  | 30        |
| 40 | Daptomycin in paediatrics: current knowledge and the need for future research. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 643-648.   | 3.0  | 22        |
| 41 | Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. <i>European Heart Journal</i> , 2015, 36, 2454-2462. | 2.2  | 94        |
| 42 | Steps forward in regulatory pathways for acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 3-8.  | 7.1  | 11        |
| 43 | Transparency in medical research: Time for a paradigm shift. <i>International Journal of Cardiology</i> , 2015, 186, 259-260.  | 1.7  | 4         |
| 44 | Changes and determination of dosing recommendations for medicinal products recently authorised in the European Union. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 903-911.  | 1.8  | 6         |
| 45 | The European Medicines Agency's strategies to meet the challenges of Alzheimer disease. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 221-222.  | 46.4 | 13        |
| 46 | Rare diseases and effective treatments: are we delivering?. <i>Lancet, The</i> , 2015, 385, 750-752.   | 13.7 | 46        |
| 47 | Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3838-3839.  | 1.6  | 9         |
| 48 | Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data from 10-Year Post-marketing Surveillance. <i>Drug Safety</i> , 2015, 38, 1211-1218.   | 3.2  | 12        |
| 49 | Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 181, 239-244.  | 1.7  | 88        |
| 50 | Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 455-461.   | 0.8  | 9         |
| 51 | Towards a framework for treatment effectiveness in schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1867.  | 2.2  | 18        |
| 52 | High Prevalence of Poor Quality Drug Prescribing in Older Individuals: A Nationwide Report From the Italian Medicines Agency (AIFA). <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69, 430-437.   | 3.6  | 86        |
| 53 | Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 1346-1353.                                    | 2.6  | 39        |
| 54 | Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. <i>Journal of Internal Medicine</i> , 2014, 275, 251-283.   | 6.0  | 540       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience. Paediatric Anaesthesia, 2014, 24, 625-631.  | 1.1  | 9         |
| 56 | Are we ready? What is missing and what is needed? A regulator's perspective. Orphanet Journal of Rare Diseases, 2014, 9, O25.   | 2.7  | 0         |
| 57 | Managed entry agreements. Orphanet Journal of Rare Diseases, 2014, 9, O27.  | 2.7  | 2         |
| 58 | Insights Into the Decision Making of Advisory Groups to the Italian Medicines Agency. Therapeutic Innovation and Regulatory Science, 2014, 48, 696-701.   | 1.6  | 4         |
| 59 | Licensing of Generic Medicines, are there Any Challenges Left? A Pharmaceutical Regulatory Perspective. Scientia Pharmaceutica, 2014, 82, 847-856.  | 2.0  | 3         |
| 60 | Reflections on Decisions Taken on Well Established Use Medicinal Products by EU Regulators and the ECJ: A Pharmaceutical Regulatory Perspective. Scientia Pharmaceutica, 2014, 82, 655-663.                                       | 2.0  | 10        |
| 61 | Validated Method to Determine Quetiapine and Norquetiapine in Microsomal Matrix by LC MS-MS: Implication in Quetiapine Metabolism. Chromatographia, 2014, 77, 75-82.  | 1.3  | 5         |
| 62 | Stamina therapies: Let the record stand. Nature, 2014, 506, 434-434.  | 27.8 | 4         |
| 63 | Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 421. | 0.8  | 77        |
| 64 | The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review. CNS Drugs, 2014, 28, 421-53.  | 5.9  | 238       |
| 65 | THE USE OF PLACEBO IN RANDOMIZED CONTROLLED TRIALS IN SCHIZOPHRENIA: A REGULATOR'S VIEW. Schizophrenia Research, 2014, 153, S14.  | 2.0  | 0         |
| 66 | Steps forward in regulatory pathways for acute and chronic heart failure. ESC Heart Failure, 2014, 1, 87-93.  | 3.1  | 4         |
| 67 | The Italian Medicines Agency Experience With Hta Scientific Advice Activities: A Comprehensive Analysis Of Three Years Of National And International Activities. Value in Health, 2014, 17, A27-A28.                              | 0.3  | 1         |
| 68 | Novel Epigenetic Target Therapy for Prostate Cancer: A Preclinical Study. PLoS ONE, 2014, 9, e98101.  | 2.5  | 25        |
| 69 | A focus on real life data concerning antidiabetic drugs: The experience of aifa monitoring registry. Value in Health, 2013, 16, A174.   | 0.3  | 0         |
| 70 | Regulatory evaluation of Glybera in Europe - two committees, one mission. Nature Reviews Drug Discovery, 2013, 12, 719-719.   | 46.4 | 54        |
| 71 | Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity. Expert Opinion on Biological Therapy, 2013, 13, 1343-1346.  | 3.1  | 10        |
| 72 | Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparency. British Journal of Clinical Pharmacology, 2013, 75, 1149-1151.   | 2.4  | 14        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | Is HCMV Vaccine an Unmet Need? The State of Art of Vaccine Development. International Journal of Immunopathology and Pharmacology, 2013, 26, 15-26.   | 2.1  | 4         |
| 74 | Analysis of <i>CYP2D6</i> Allele Frequencies and Identification of Novel SNPs and Sequence Variations in Sardinians. ISRN Genetics, 2013, 2013, 1-10.   | 0.2  | 5         |
| 75 | Genotyping of CYP2D6 Polymorphisms by MALDI-TOF Mass Spectrometry in Sardinian People. ISRN Genetics, 2013, 2013, 1-10.   | 0.2  | 1         |
| 76 | DSM-5 and clinical trials in psychiatry: challenges to come?. Nature Reviews Drug Discovery, 2012, 11, 583-584.   | 46.4 | 7         |
| 77 | Discriminative Hypomania Checklist-32 Factors in Unipolar and Bipolar Major Depressive Patients. Psychopathology, 2012, 45, 390-398.  | 1.5  | 18        |
| 78 | Contents Vol. 45, 2012. Psychopathology, 2012, 45, I-IV.  | 1.5  | 0         |
| 79 | The Italian post-marketing registries. Pharmaceutical Programming, 2012, 5, 57-60.  | 0.1  | 15        |
| 80 | European licensing of maintenance treatment in schizophrenia. Lancet, The, 2012, 380, 562-563.  | 13.7 | 1         |
| 81 | The placebo arm in clinical studies for treatment of Psychiatric Disorders: A Regulatory Dilemma. European Neuropsychopharmacology, 2012, 22, 804-811.  | 0.7  | 10        |
| 82 | PIN57 Public Expenditure for Antiretroviral Treatment and Projected Cost-Savings After the Entry of Generic Antiretrovirals in the Italian Pharmaceutical Market. Value in Health, 2012, 15, A247.  | 0.3  | 0         |
| 83 | Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-]pyrazole CB2 Ligands Using Molecular Hybridization Based on Scaffold Hopping. Open Medicinal Chemistry Journal, 2012, 6, 1-14.  | 2.4  | 12        |
| 84 | NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile. Behavioural Brain Research, 2012, 234, 192-204.  | 2.2  | 31        |
| 85 | PHP39 The "Weight" of Orphan Drugs in the European Pharmaceutical Policy. A Focus on the Expenditure and the Utilization of Orphan Drugs in Five European Union Countries. Value in Health, 2012, 15, A20.  | 0.3  | 1         |
| 86 | PHP99 How to Deal With Decision Uncertainty? The Italian Experience With Managed Entry Agreements. Value in Health, 2012, 15, A31.  | 0.3  | 1         |
| 87 | Subthreshold depression in older subjects: An unmet therapeutic need. Journal of Nutrition, Health and Aging, 2012, 16, 909-913.  | 3.3  | 17        |
| 88 | Unexplained Somatic Symptoms during Major Depression: Prevalence and Clinical Impact in a National Sample of Italian Psychiatric Outpatients. Psychopathology, 2011, 44, 116-124.   | 1.5  | 25        |
| 89 | Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice. Behavioural Brain Research, 2011, 217, 432-438.   | 2.2  | 33        |
| 90 | Qualification opinion of novel methodologies in the prodementia stage of Alzheimer's disease: Cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden " Regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials. European Neuropsychopharmacology, 2011, 21, 781-788. | 0.7  | 49        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Prevalence and diagnostic distribution of medically unexplained painful somatic symptoms across 571 major depressed outpatients. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 217.  | 2.2 | 10        |
| 92  | Are "social drugs" (tobacco, coffee and chocolate) related to the bipolar spectrum?. <i>Journal of Affective Disorders</i> , 2011, 133, 227-233.  | 4.1 | 17        |
| 93  | Novel approaches to drug-placebo difference calculation: evidence from short-term antidepressant drug-trials. <i>Human Psychopharmacology</i> , 2011, 26, 307-312.  | 1.5 | 4         |
| 94  | Oct4 expression in in vitro produced sheep blastocysts and embryonic stem like cells. <i>Cell Biology International</i> , 2010, 34, 53-60.  | 3.0 | 22        |
| 95  | Quetiapine anxiolytic-like effect in the Vogel conflict test is serotonin dependent. <i>Behavioural Pharmacology</i> , 2010, 21, 649-653.   | 1.7 | 11        |
| 96  | Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry. <i>Pharmacogenomics</i> , 2010, 11, 559-571.   | 1.3 | 12        |
| 97  | 1-(2,4-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. <i>Neurobiology of Disease</i> , 2010, 37, 177-185. | 4.4 | 101       |
| 98  | Antinociceptive activity of $\delta^9$ -tetrahydrocannabinol non-ionic microemulsions. <i>International Journal of Pharmaceutics</i> , 2010, 393, 239-244.  | 5.2 | 7         |
| 99  | A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats. <i>European Psychiatry</i> , 2010, 25, 92-100.  | 0.2 | 16        |
| 100 | Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in rats. <i>European Journal of Pharmacology</i> , 2009, 620, 36-41.   | 3.5 | 6         |
| 101 | Synthesis and in vitro Evaluation of Trifluoroethylamine Analogues of Enkephalins. <i>ChemMedChem</i> , 2009, 4, 1416-1420.   | 3.2 | 9         |
| 102 | Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 4715-4719.   | 2.2 | 8         |
| 103 | Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 319-331.  | 5.0 | 23        |
| 104 | Are changes in the pharmacokinetic (PK) and pharmacodynamic (PD) properties of antipsychotics able to improve efficacy and safety?. <i>Annals of General Psychiatry</i> , 2008, 7, .  | 2.7 | 0         |
| 105 | Delta-9-tetrahydrocannabinol differently affects striatal c-Fos expression following haloperidol or clozapine administration. <i>European Journal of Pharmacology</i> , 2008, 598, 16-20.   | 3.5 | 2         |
| 106 | Building a virtual archive using brain architecture and Web 3D to deliver neuropsychopharmacology content over the Internet. <i>Computer Methods and Programs in Biomedicine</i> , 2008, 90, 124-136.   | 4.7 | 4         |
| 107 | Practical Issues with Amisulpride in the Management of Patients with Schizophrenia. <i>Clinical Drug Investigation</i> , 2008, 28, 465-477.   | 2.2 | 28        |
| 108 | Contrasting effects of diazepam and repeated restraint stress on latent inhibition in mice. <i>Behavioural Brain Research</i> , 2007, 183, 147-155.   | 2.2 | 11        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy. <i>European Psychiatry</i> , 2007, 22, 267-275.   | 0.2 | 65        |
| 110 | 3-{2-[Bis-(4-fluorophenyl)methoxy]ethyl}-6-substituted-3,6-diazabicyclo[3.1.1]heptanes as novel potent dopamine uptake inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 3748-3755.  | 3.0 | 10        |
| 111 | Effects of acute and chronic valproate treatments on p-CREB levels in the rat amygdala and nucleus accumbens. <i>Brain Research</i> , 2007, 1141, 15-24.   | 2.2 | 22        |
| 112 | Eficacia de los antipsicóticos: relación con la ocupación óptima de los receptores D2. <i>European Psychiatry (Ed Española)</i> , 2007, 14, 325-334.   | 0.0 | 0         |
| 113 | Tricyclic Pyrazoles. 4. Synthesis and Biological Evaluation of Analogues of the Robust and Selective CB2 Cannabinoid Ligand 1-(2,4-Dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7502-7512.                      | 6.4 | 68        |
| 114 | Evolutionary Psychopharmacology, Mental Disorders, and Ethical Behavior. , 2006, , 97-120.   |     | 2         |
| 115 | Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 3309-3320.  | 3.0 | 51        |
| 116 | Effect of 1-butanol on the microstructure of lecithin/water/tripalmitin system. <i>Chemistry and Physics of Lipids</i> , 2005, 135, 147-156.   | 3.2 | 30        |
| 117 | Modulation of ATP-mediated contractions of the rat vas deferens through presynaptic cannabinoid receptors. <i>European Journal of Pharmacology</i> , 2005, 525, 150-153.   | 3.5 | 7         |
| 118 | Effect of $\delta^9$ -tetrahydrocannabinol on phosphorylated CREB in rat cerebellum: An immunohistochemical study. <i>Brain Research</i> , 2005, 1048, 41-47.  | 2.2 | 34        |
| 119 | Evaluation of Tamsulosin and Alfuzosin Activity in the Rat Vas Deferens: Relevance to Ejaculation Delays. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 710-717.   | 2.5 | 22        |
| 120 | Tricyclic Pyrazoles. 3. Synthesis, Biological Evaluation, and Molecular Modeling of Analogues of the Cannabinoid Antagonist 8-Chloro-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7351-7362. | 6.4 | 39        |
| 121 | Five mutations in the GABAA $\alpha 6$ gene 5' flanking region are associated with a reduced basal and ethanol-induced $\alpha 6$ upregulation in mutated Sardinian alcohol non-preferring rats. <i>Molecular Brain Research</i> , 2005, 137, 252-257.   | 2.3 | 7         |
| 122 | Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia. <i>Psychiatric Services</i> , 2004, 55, 997-1005.   | 2.0 | 69        |
| 123 | Consensus on the Use of Substituted Benzamides in Psychiatric Patients. <i>Neuropsychobiology</i> , 2004, 50, 134-143.   | 1.9 | 42        |
| 124 | Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol. <i>European Journal of Pharmacology</i> , 2004, 483, 65-69.   | 3.5 | 12        |
| 125 | The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. <i>European Journal of Pharmacology</i> , 2004, 504, 61-64.  | 3.5 | 51        |
| 126 | The cerebellar GABAA $\alpha 6$ subunit is differentially modulated by chronic ethanol exposure in normal (R100R) and mutated (Q100Q) sNP rats. <i>Brain Research</i> , 2004, 998, 148-154.  | 2.2 | 7         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Immunocytochemical study of the forebrain serotonergic innervation in Sardinian alcohol-preferring rats. <i>Psychopharmacology</i> , 2004, 172, 341-351.  | 3.1 | 33        |
| 128 | Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 1921-1933.                                | 3.0 | 36        |
| 129 | Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by haloperidol in mice. <i>Neuropharmacology</i> , 2004, 47, 128-135.   | 4.1 | 13        |
| 130 | Haloperidol versus risperidone on rat "early onset" vacuous chewing. <i>Behavioural Brain Research</i> , 2004, 149, 9-16.   | 2.2 | 20        |
| 131 | Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic. <i>Psychopharmacology</i> , 2003, 167, 79-84.                                | 3.1 | 55        |
| 132 | Characterization of wild-type (R100R) and mutated (Q100Q) GABAA $\alpha 6$ subunit in Sardinian alcohol non-preferring rats (sNP). <i>Brain Research</i> , 2003, 967, 98-105.   | 2.2 | 11        |
| 133 | Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. <i>European Journal of Pharmacology</i> , 2003, 459, 97-105.  | 3.5 | 72        |
| 134 | Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients. <i>Journal of Affective Disorders</i> , 2003, 73, 75-85.  | 4.1 | 89        |
| 135 | In vitro evidence for the presence of [3 H]-haloperidol uptake in rat brain. <i>British Journal of Pharmacology</i> , 2003, 138, 188-192.   | 5.4 | 5         |
| 136 | Haloperidol, but not clozapine, produces dramatic catalepsy in $\Delta^9$ -THC-treated rats: possible clinical implications. <i>British Journal of Pharmacology</i> , 2003, 140, 520-526.   | 5.4 | 30        |
| 137 | Molecular characterization of new polymorphisms at the $\alpha 2$ , $\alpha 1$ , $\alpha 3$ GABAA receptor subunit genes associated to a rat nonpreferring ethanol phenotype. <i>Molecular Brain Research</i> , 2003, 110, 289-297. | 2.3 | 11        |
| 138 | Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 363-370.  | 2.5 | 89        |
| 139 | The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. <i>Molecular Psychiatry</i> , 2002, 7, 247-253.   | 7.9 | 54        |
| 140 | Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid. <i>European Journal of Endocrinology</i> , 2002, 147, 255-261.   | 3.7 | 46        |
| 141 | Effect of the amisulpride isomers on rat catalepsy. <i>European Journal of Pharmacology</i> , 2002, 444, 69-74.   | 3.5 | 13        |
| 142 | Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect. <i>European Journal of Pharmacology</i> , 2002, 447, 109-114.  | 3.5 | 9         |
| 143 | Effect of the amisulpride isomers on rat prolactinemia. <i>European Journal of Pharmacology</i> , 2002, 448, 263-266.   | 3.5 | 4         |
| 144 | Reduced TH-immunoreactive fibers in the limbic system of Sardinian alcohol-preferring rats. <i>Brain Research</i> , 2002, 924, 242-251.   | 2.2 | 23        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Reduced DAT- and DBH-immunostaining in the limbic system of Sardinian alcohol-preferring rats. <i>Brain Research</i> , 2002, 948, 192-202.  | 2.2 | 16        |
| 146 | Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigrostriatal dopaminergic neurons directly related to "early onset" vacuous chewing. <i>European Journal of Neuroscience</i> , 2002, 15, 1187-1196. | 2.6 | 42        |
| 147 | Lead intoxication during intrauterine life and lactation but not during adulthood reduces nucleus accumbens dopamine release as studied by brain microdialysis. <i>Toxicology Letters</i> , 2001, 121, 199-206.   | 0.8 | 32        |
| 148 | The R100Q mutation of the GABA <sub>A</sub> $\alpha$ 6 receptor subunit may contribute to voluntary aversion to ethanol in the sNP rat line. <i>Molecular Brain Research</i> , 2001, 87, 263-270.   | 2.3 | 37        |
| 149 | The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. <i>European Journal of Neuroscience</i> , 2001, 13, 409-412.   | 2.6 | 101       |
| 150 | Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. <i>Molecular Psychiatry</i> , 2001, 6, 657-664.  | 7.9 | 174       |
| 151 | ( $\alpha$ )S amisulpride binds with high affinity to cloned dopamine D3 and D2 receptors. <i>European Journal of Pharmacology</i> , 2001, 432, 143-147.  | 3.5 | 20        |
| 152 | The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. <i>European Journal of Neuroscience</i> , 2000, 12, 1123-1127.  | 2.6 | 88        |
| 153 | The role of stress in the pathophysiology of the dopaminergic system. <i>Molecular Psychiatry</i> , 2000, 5, 14-21.   | 7.9 | 270       |
| 154 | Is there an evolutionary mismatch between the normal physiology of the human dopaminergic system and current environmental conditions in industrialized countries?. <i>Molecular Psychiatry</i> , 2000, 5, 467-475.   | 7.9 | 48        |
| 155 | The 5-HT <sub>2</sub> antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex. <i>Molecular Psychiatry</i> , 2000, 5, 673-677.  | 7.9 | 20        |
| 156 | $\delta$ -9-Tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain. <i>European Journal of Neuroscience</i> , 1998, 10, 1743-1751.  | 2.6 | 35        |
| 157 | Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marijuana. <i>Molecular Brain Research</i> , 1998, 58, 240-245.  | 2.3 | 89        |
| 158 | Rat tyrosine hydroxylase gene polymorphisms. <i>Molecular Brain Research</i> , 1997, 45, 345-348.   | 2.3 | 2         |
| 159 | Fluoxetine-induced conditioned place preference: A preliminary study. , 1997, 25, 309-311.  |     | 12        |
| 160 | Correlation between increased AP-1/NGF binding activity and induction of nerve growth factor transcription by multiple signal transduction pathways in C6-2B glioma cells. <i>Molecular Brain Research</i> , 1996, 35, 1-10.                                    | 2.3 | 32        |
| 161 | Circulating levels of anticonvulsant metabolites of progesterone in women with partial epilepsy in the intercritical phase. <i>Italian Journal of Neurological Sciences</i> , 1996, 17, 277-281.  | 0.1 | 5         |
| 162 | Chronic imipramine, l-sulpiride and mianserin decrease corticotropin releasing factor levels in the rat brain. <i>Neuroscience Letters</i> , 1995, 192, 121-123.  | 2.1 | 21        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Sleep deprivation in the rat: an animal model of mania. <i>European Neuropsychopharmacology</i> , 1995, 5, 89-93.   | 0.7 | 156       |
| 164 | Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression. <i>European Journal of Pharmacology</i> , 1994, 262, 107-111.  | 3.5 | 57        |
| 165 | ACTH-induced mitochondrial DBI receptor (MDR) and diazepam binding inhibitor (DBI) expression in adrenals of hypophysectomized rats is not cause-effect related to its immediate steroidogenic action. <i>Life Sciences</i> , 1993, 53, 1137-1147.                        | 4.3 | 15        |
| 166 | Identification of nine tissue-specific transcription factors of the hepatocyte nuclear factor 3/forkhead DNA-binding-domain family.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 3948-3952.                        | 7.1 | 237       |
| 167 | Cloning and tissue-specific functional characterization of the promoter of the rat diazepam binding inhibitor, a peptide with multiple biological actions.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 8439-8443. | 7.1 | 28        |
| 168 | The calcium antagonist PN 200-110 inhibits the reinforcing properties of cocaine. <i>Brain Research Bulletin</i> , 1991, 26, 445-447.   | 3.0 | 75        |
| 169 | Flunarizine attenuates cocaine-induced inhibition of A dopaminergic neurons. <i>Pharmacological Research</i> , 1991, 24, 197-203.   | 7.1 | 8         |
| 170 | Inhibition of [3H]dopamine uptake by flunarizine. <i>European Journal of Pharmacology</i> , 1991, 203, 67-69.   | 3.5 | 13        |
| 171 | Conditioned place preference induced by ethanol in a rat line selected for ethanol preference. <i>Pharmacological Research</i> , 1990, 22, 48.  | 7.1 | 12        |
| 172 | The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+). <i>Neuroscience Letters</i> , 1990, 117, 129-133.  | 2.1 | 73        |
| 173 | Calcium receptor antagonists modify cocaine effects in the central nervous system differently. <i>European Journal of Pharmacology</i> , 1990, 190, 217-221.  | 3.5 | 92        |
| 174 | Flunarizine potentiates cocaine-induced dopamine release and motor stimulation in rats. <i>European Journal of Pharmacology</i> , 1990, 190, 223-227.   | 3.5 | 17        |
| 175 | Stress increases noradrenaline release in the rat frontal cortex: Prevention by diazepam. <i>European Journal of Pharmacology</i> , 1990, 176, 229-231.   | 3.5 | 69        |
| 176 | Nimodipine inhibits cocaine-induced dopamine release and motor stimulation. <i>European Journal of Pharmacology</i> , 1990, 176, 245-246.   | 3.5 | 37        |
| 177 | Brain dialysis and dopamine: does the extracellular concentration of dopamine reflect synaptic release?. <i>European Journal of Pharmacology</i> , 1990, 180, 85-90.  | 3.5 | 37        |
| 178 | Differential postmortem release of noradrenaline and dopamine from rat brain. <i>Psychopharmacology</i> , 1989, 98, 562-563.  | 3.1 | 8         |
| 179 | Brain dialysis provides evidence for D2-dopamine receptors modulating noradrenaline release in the rat frontal cortex. <i>European Journal of Pharmacology</i> , 1989, 163, 393-395.  | 3.5 | 36        |
| 180 | Are D1 dopamine receptor agonists potential antidepressants?. <i>Pharmacological Research Communications</i> , 1988, 20, 1121-1122.   | 0.2 | 10        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 181 | Sustainable Reimbursements: Towards a Unified Framework for Pricing Drugs with Significant Uncertainties. SSRN Electronic Journal, 0, , . | 0.4 | 1         |